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Non-invasive imaging technologies to visualize the location and functionality of T cells
are of great value in immunology. Here, we describe the design and generation
of a transgenic mouse in which all T cells constitutively express green-emitting
click-beetle luciferase (CBG99) while expression of the red-emitting firefly luciferase
(PpyRE9) is induced by Nuclear Factor of Activated T cells (NFAT) such as during
T cell activation, which allows multicolor bioluminescence imaging of T cell location
and function. This dual-luciferase mouse, which we named TbiLuc, showed high
constitutive luciferase expression in lymphoid organs such as lymph nodes and the
spleen. Ex vivo purified CD8+ and CD4+ T cells both constitutively expressed luciferase,
whereas B cells showed no detectable signal. We cross-bred TbiLuc mice to T cell
receptor-transgenic OT-I mice to obtain luciferase-expressing naïve CD8+ T cells with
defined antigen-specificity. TbiLuc∗OT-I T cells showed a fully antigen-specific induction
of the T cell activation-dependent luciferase. In vaccinated mice, we visualized T cell
localization and activation in vaccine-draining lymph nodes with high sensitivity using
two distinct luciferase substrates, D-luciferin and CycLuc1, of which the latter specifically
reacts with the PpyRE9 enzyme. This dual-luciferase T cell reporter mouse can be applied
in many experimental models studying the location and functional state of T cells.
Keywords: T cell, activation, mouse, dual-color, luciferase, bioluminescence, imaging, reporter
INTRODUCTION
Bioluminescence imaging (BLI) is an optical molecular imaging technique based on the emission
of light produced by luciferase enzymes expressed in cells or animals. It has been extensively used
to study gene expression, using genetic constructs in which expression of the luciferase is driven
by the promoter of the gene of interest (1). A common application of BLI is the monitoring of
tumor cell growth using luciferase-expressing tumor cells (2). Besides functioning as a quantitative
measure for cell number, BLI also provides information on cell viability as the light-producing
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reaction mediated by firefly or click beetle luciferases requires
ATP, oxygen and Mg2+, thus, the context of a living cell (3,
4). Commonly, retroviral or lentiviral constructs harboring the
luciferase gene coupled to a specific promoter are designed to
integrate the luciferase gene into cells by viral transduction.
Alternatively, luciferase-transgenic reporter mouse strains can
be developed using similar constructs, requiring more time
and effort but becoming a source of luciferase-expressing cells
without the need for further modification. Such transgenic
models are especially valuable if the cells of interest are to be
studied in their natural, unmodified state.
BLI technology is highly suited to analyze the immune system
in vivo, because it allows real-time visualization of the typically
strong dynamics of many immune cells, which often change
location and expand or contract in number over short periods of
time. These characteristics are particularly true for T cells, which
are found in high numbers in lymphoid organs such as the spleen
and lymph nodes, but also circulate in the bloodstream to patrol
the body and enter peripheral tissues in case these harbor their
target. These properties make T cells an attractive target for BLI.
Thus far, many attempts to create luciferase-expressing T cells
have used viral transduction of T cells. However, T cells in their
untouched natural state, immunologically referred to as ‘naïve T
cells’, are practically impossible to transduce. Therefore, in order
to allow their transduction, T cells are first activated in vitro
to facilitate their transduction, and then rested for several days
before use in an experiment (5–9). However, the transition of a
T cell from the naïve to the activated state is not fully reversible,
as T cell activation starts transcriptional programs that cannot
be reversed. Hence, although commonly overlooked, the results
obtained with BLI of such transduced T cells cannot be directly
compared to the natural situation in which T cells are naïve
when they first encounter their target. These drawbacks have led
to the production of a number of T cell luciferase-transgenic
mouse models to allow the tracking of T cells (10–12). While
definitely a step forward from using transduced T cells, these
single-luciferase transgenic models have the limitation that they
only provide information on the location of T cells, but not their
functional state.
Recently, Szyska et al. published a dual reporter mouse
that ubiquitously expresses Renilla luciferase and NFAT-driven
click beetle red luciferase CBRed (13). Dual-color imaging is
achieved by using the substrates Coelenterazine and D-luciferin.
Considering that Renilla luciferase is less bright than the green
luciferase mutant CBG99 (14) and that Coelenterazine substrates
give higher background than D-luciferin and show suboptimal
bioavailability and stability (15, 16), we aimed to create a system
that does not employ Coelenterazine but shows good sensitivity
for T cell imaging, especially for longitudinal studies. We have
previously shown that the click-beetle green luciferase mutant
CBG99 and the red-emitting firefly mutant PpyRE9 can be
efficiently combined for multicolor in vivo bioluminescence
imaging of transplanted cells previously transduced with a single
luciferase, using the substrate D-luciferin (17). In this study, we
show the design and generation of a transgenic mouse model
called TbiLuc, whose combination of a constitutive and an
inducible luciferase in T cells allows dual-color visualization of
T cell location and function. In TbiLuc, all T cells constitutively
express the green CBG99 luciferase driven by the human
CD2 promoter, and the transcription factor Nuclear Factor of
Activated T cells (NFAT) induces the expression of the red
PpyRE9 luciferase in addition.
We show that luciferase expression is restricted to T cells,
and that antigen-specific or non-specific activation of T cells
successfully induces the expression of the NFAT-dependent
luciferase. As the expression level of the two luciferases influences
the ability to efficiently separate the two light signals in vivo
using a single substrate, we combined the recently developed
luciferase substrate CycLuc1 as a specific substrate for firefly
luciferases (such as PPyRE9) (18) with D-luciferin as a substrate
for the CBG99 enzyme. As we show that CycLuc1 is not a
functionally efficient substrate for CBG99, we could efficiently
separate light signals in vivo. Furthermore, we cross-bred TbiLuc
mice to T cell receptor-transgenic OT-I mice and subsequently
localized vaccine-specific CD8+ T cells in lymphoid organs and
visualized their activation upon vaccination. Altogether, we have
developed a dual-luciferase T cell reporter mouse that allows
live bioluminescence imaging of T cell location and function,
which has numerous possible applications in many experimental
models where T cells play a central role.
MATERIALS AND METHODS
Mice and Cell Lines
The following construct was designed for the generation of the
TbiLuc transgenic mouse. The PpyRE9 gene [Photinus pyralis
red-emitting luciferase 9, a kind gift of Prof. Branchini (19)] was
cloned downstream of 3 repetitive NFAT response elements and
minimal promoter derived from the pGL4.30 plasmid (Promega,
Madison, USA). The sequence of the human CD2 promoter
was cloned upstream of the CBG99 green click beetle luciferase
gene (20, 21). These two cassettes were cloned to form a
bidirectional construct, separated by an insulator. TbiLuc mice
were generated by injection of the bicistronic construct into
pronuclei of fertilized oocytes of CBA∗C57BL/6 mice. In the
pups born the presence of the transgene was determined by
a specific PCR using genomic DNA from tail biopsy and its
activity/function was measured by evaluation of light emission
from tail-vein blood after addition of the luciferase substrate
D-luciferin. Mice were back-crossed to the C57BL/6 strain for
several generations before use in experiments. Albino B6 mice
(tyrosinase-deficient immunocompetent C57BL/6 mice), TbiLuc
mice (dual T cell luciferase transgenic mice), OT-I mice (T cell
receptor-transgenic mice carrying the CD45.1 congenic marker)
and crossed TbiLuc∗OT-I mice were bred in the animal breeding
facility of the Leiden University Medical Center, the Netherlands.
All experiments were approved by the animal ethical committee
of Leiden University. D1 is a GM-CSF-dependent immature
dendritic cell line derived from C57BL/6 mice, and B3Z is an
OVA-specific CD8T cell hybridoma carrying the lacZ reporter
gene induced by NFAT (22, 23). Cell lines were assured to be free
of rodent viruses andMycoplasma by regular PCR analysis. Cells
were cultured as previously described (24).
Frontiers in Immunology | www.frontiersin.org 2 January 2019 | Volume 9 | Article 3097
Kleinovink et al. Dual-Color T Cell Imaging
Bioluminescence Imaging (BLI)
In Vitro
Cell samples were prepared for in vitro BLI analysis in sterile
black-walled flat-bottom 96-wells plates (Greiner, Alphen aan
den Rijn, The Netherlands). Cells were suspended in 100 µL PBS
containing 1mMD-luciferin potassium salt (SynChem, Felsberg,
Germany) or 0.1mM CycLuc1 (Aobious, Gloucester, MA, USA),
incubated for 5min at 37◦C. BLI imaging was performed using
an IVIS Spectrum small animal imager (PerkinElmer, Waltham,
MA) that measured the light signal using open filter and a
series of 20 nm wavelength band filters from 500 to 700 nm,
with an acquisition time of 30 s. Accompanying LivingImage 4.2
software (Perkin Elmer) was used for spectral unmixing of the
full-spectrummeasurement to identify individual signals in vitro.
Ex Vivo
For characterization of the TbiLuc model, a group of 3 TbiLuc
mice were injected intraperitoneally with 150 mg/kg D-luciferin,
anesthetized by isoflurane inhalation and imaged after 10min
(peak of emission) using an IVIS Spectrum imager set at the
“open” filter with an exposure time of 60 s. Another group of
3 TbiLuc mice were injected intraperitoneally with 7,6 mg/kg
CycLuc1, left for 5min and anesthetized by isoflurane inhalation
for IVIS imaging. Next, organs from TbiLuc mice were taken
out and rinsed in PBS before BLI analysis, using an acquisition
time of 30 s. Signal quantification in specific regions of interest
(ROIs) was performed depicting regions of interest (ROIs)
corresponding to the whole organ and signals were corrected for
background by subtracting the signal from the same size of ROIs
placed at irrelevant positions. Data are reported as photons flux
per mg of tissue.
In Vivo
Mice (n = 8) were injected with 150 mg/kg D-luciferin,
anesthetized by isoflurane inhalation and imaged after 10min
(peak of emission) using the “open” filter and 560 nm filter with
an exposure time of 30 seconds. After 3 h, mice were imaged to
assure that no D-luciferin-mediated signal was present anymore,
and mice were subsequently injected intraperitoneally with 7,6
mg/kg CycLuc1, left for 5min and anesthetized by isoflurane
inhalation. This concentration of CycLuc1 was chosen as a
maximum injectable dose given its low solubility. Mice were
imaged using open filter and 620 nm filter with an exposure
time of 30 s. Signal quantification in specific regions of interest
(ROIs) was performed by using fixed-size and fixed-position
ROIs throughout the experiments, and signals were corrected
for background by subtracting the signal from ROIs placed at
irrelevant positions.
Isolation of Immune Cells
Immune cells were obtained from the spleen by mashing on
70µm cell strainers (BD Biosciences, San Jose, CA, USA) to
create single-cell suspensions, followed by erythrocyte lysis.
Then, CD4+ and CD8+ T cells were isolated separately by
negative magnetic selection (BD IMag enrichment kits), B cells
by positive magnetic selection of B220+ cells (BD IMag), while
NK cells and myeloid cells were obtained by FACS-sorting
for CD3−/NK1.1+/NKp46+ (NK cells) and CD3−/CD11b+
(myeloid cells).
T Cell Activation in vitro
T cells isolated from spleens of TbiLuc or TbiLuc∗OT-Imice were
stimulated overnight with 100 ng/mL Phorbol 12-myristate 13-
acetate (PMA) + 1500 ng/mL ionomycin (both Sigma-Aldrich,
St. Louis, MO, USA), with agonistic anti-CD3 and anti-CD28
antibodies (BD Biosciences) pre-coated at 1µg/mL (unless
indicated otherwise) at 37◦C for 30min, or with 50,000 D1
dendritic cells pre-loaded with OVA immune complexes. OVA
immune complexes were formed by incubating a 1:300mass ratio
of OVA protein (Worthington, Lakewood, NJ, USA) and anti-
OVA antibody (LSBio, Seattle, WA, USA) for 30min at 37◦C,
after which the immune complexes were added to D1 dendritic
cells and incubated overnight. Unloaded D1 cells were incubated
overnight in parallel to serve as control cells.
Adoptive Transfer and Vaccination
Adoptive transfer consisted of 1 million purified CD8+ OT-
I cells (unless stated otherwise) isolated as described above,
injected intravenously in 200 µL PBS in the tail vein. Vaccination
consisted of subcutaneous injection of 1 million (unless indicated
otherwise) D1 cells pre-loaded with OVA immune complexes, or
unloaded control D1 cells, in 50 µL PBS in the tail-base region.
Western Blot
Expression of PpyRE9 luciferase by activated T cells was
confirmed by Western Blot. T cells were isolated and stimulated
overnight as described above. Then, 3∗106 cells were lysed and
the total protein content of each sample was determined by a
Pierce BCA protein assay kit (Thermo Scientific, Rockford, USA).
Next, 20 µg of total cell extract was applied to a 10% SDS-
PAGE and transferred onto a nitrocellulose membrane. After
washing, the membrane was incubated overnight with rabbit
anti-luciferase polyclonal antibody in TPBS at 1/500 dilution
(Fitzgerald, Acton, USA). The GAPDH antibody (Cell Signaling
Technology, Danvers, MA, USA) was used to correct for the
amount of total protein. The blots were washed, exposed to
an HRP-conjugated secondary antibody for 1 h, and detected
using enhanced chemiluminescence (ECL) reagents (Thermo
Scientific). Detection of ECL signals was performed with the
IVIS Spectrum and quantification of bands using Living Image
Software 4.2.
Flow Cytometry
Before adoptive transfer of CD8T cells, their CD8-purity and
naïve phenotype was assessed by flow cytometry. In short, spleen
cells were suspended in FACS buffer (PBS with 0.5% FCS and
0.02% sodium azide), surface-stained with antibodies against
CD8β, CD44, CD45.1, and CD62L (BioLegend, San Diego, CA,
USA) and analyzed on a BD Accuri C6 flow cytometer. Analysis
was performed on FlowJo software (FlowJo, USA).
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 6.0
software. Data are shown as the mean ± SEM for each group,
and comparison of groups was performed by two-tailed Student’s
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FIGURE 1 | Design and development of the dual-luciferase transgenic TbiLuc mouse. (A) Schematic overview of the dual-luciferase reporter bicistronic vector. NFAT,
nuclear factor of activated T cells; CBG99, click beetle green luciferase 99; PpyRE9, Photinus pyralis red-emitting luciferase 9. (B) Bioluminescence measurement of a
TbiLuc mouse using the D-luciferin substrate, showing strong constitutive CBG99 luciferase expression in lymphoid organs. Lymphoid organs are indicated: LN,
lymph node; spl, spleen; thy, thymus. The abdomen is shaved to reduce signal absorption. (C) Representative images and quantification of luciferase signal in several
lymphoid and non-lymphoid organs of TbiLuc mice (n = 3, mean + SEM). LNs, lymph nodes; ing., inguinal; ax., axillary.
t-test. Statistical differences were considered significant at
p < 0.05.
RESULTS
Design and Development of the
Dual-Luciferase Transgenic TbiLuc Mouse
We designed a bicistronic vector containing the click beetle green
luciferase (CBG99) sequence under the control of the human
CD2 (hCD2) promoter and the red-emitting firefly luciferase
(PpyRE9) sequence under the control of the nuclear factor
of activated T cells (NFAT) minimal promoter (Figure 1A).
BackgroundNFAT expression in naïve T cells is low and increases
strongly after T cell activation, making it an ideal promoter to
visualize activated T cells. The hCD2 promoter is expressed in
both T cells and B cells in humans, but is T cell-specific when
used in mice (20). This bicistronic vector was used to generate
the TbiLuc transgenic mouse on a B6/CBA mixed background.
Founders were selected based on high light emission in blood and
further back-crossed more than 10 times toward B6 background.
The CD2-driven CBG99 luciferase was constitutively expressed
in lymphoid organs, which was evident both in live in vivo
BLI and upon dissecting lymphoid and non-lymphoid organs
showing on average a 1,000-fold higher signal in lymphoid organs
than in non-lymphoid organs (Figures 1B,C).
Luciferase Expression Is Restricted to T
Cells
Next, we analyzed in more detail which cells in the lymphoid
organs express luciferase by isolating CD4T cells, CD8T cells, B
cells, NK cells and myeloid cells from the spleens of TbiLuc mice.
Constitutive expression of CBG99 luciferase in unstimulated
cells was completely restricted to T cells, as the other cell types
showed no detectable bioluminescence signal (Figure 2A, top
half). CD8T cells produced a two-fold higher luciferase activity
than CD4T cells. The luciferase activity was proportional to the
number of T cells. In parallel, we tested the validity of the dual-
luciferase construct by stimulating these isolated immune cells
with PMA and ionomycin, which are chemical compounds often
used in combination to trigger NFAT by activating the protein
kinase C (PKC) pathway and increasing intracellular levels
of calcium, respectively. Also after PMA/ionomycin treatment,
strong luciferase activity was observed only in T cells, except for
a weakly detectable signal in NK cells (Figure 2A, bottom half).
T Cell Activation Results in NFAT-Induced
Luciferase Expression
We next analyzed if the increased light signal after
PMA/ionomycin treatment was mediated by the NFAT-
driven PpyRE9 luciferase. A spectral unmixing algorithm was
applied to separate the independent emission spectra within
the sample and quantify these spectra separately. Two distinct
emission patterns were identified corresponding to the emission
spectra of the green CBG99 and the red PpyRE9 luciferases
(Figure 2B). By representing the unmixed signals in artificial
green and red colors, the emission spectra of the two luciferases
can be assessed per single sample. Unstimulated naïve T cells
expressed only the constitutive hCD2-driven CBG99 luciferase,
while PMA/ionomycin treatment induced the expression of
NFAT-driven red PpyRE9 luciferase, resulting in a yellow color
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FIGURE 2 | T cell-specific expression of constitutive and inducible luciferases in the TbiLuc mouse. T cells, B cells, NK cells, and myeloid cells were isolated from the
spleen of TbiLuc mice, plated in different numbers, and stimulated overnight with PMA + ionomycin to activate the NFAT-inducible red luciferase. Representative data
from two independent experiments. (A) Luciferase expression is restricted to CD4 and CD8T cells and signal strength correlates to the number of T cells, both in
unstimulated (top half) and PMA+ionomycin stimulated cells (bottom half). (B) Spectral unmixing of the total BLI signal identifies two emission spectra matching the
constitutive CBG99 luciferase (green) and the NFAT-inducible PpyRE9 luciferase (red). (C) Spectral unmixing applied to the signals from Figure A indicates that naïve T
cells express only constitutive CBG99 luciferase (top half, green color), while activated T cells express both luciferases (bottom half, overlay of green and red signals
yielding yellow). NK cells produce PpyRE9 after stimulation but do not express CBG99 luciferase. (D) Fold induction of NFAT-luciferase expression in TbiLuc cells after
PMA+ionomycin stimulation compared to unstimulated cells. Signals are corrected for differences in constitutive hCD2-luciferase expression. Baseline expression
(1-fold) is indicated by the dotted line. Representative data of two independent experiments with n = 3 samples per group each (n = 1 for NK cells). Mean + SD, the
fold induction within a cell subset is independent of cell number as there are no significant differences within CD4T cells or within CD8T cells (one-way ANOVA).
based on overlaying green and red colors (Figure 2C). The low
signal observed in NK cells after PMA/ionomycin treatment was
confirmed to be NFAT-induced, as shown by the red color. The
induction of PpyRE9 luciferase expression by PMA/ionomycin
treatment was further analyzed by Western Blotting, showing
a clear presence of PpyRE9 luciferase protein band 24 h after
stimulation of TbiLuc CD8+ T cells with PMA/ionomycin
(Supplementary Figure 1a). We calculated the fold induction
of the NFAT-luciferase after unmixing of signals and correction
of red PpyRE9 signals (representing NFAT-driven expression)
for the green CBG99 signals (representing constitutive T cell
expression). For CD4+ T cells we found an average of 2.5- ±
0.5 -fold induction, for CD8+ T cells an average of 1.5- ± 0.1
-fold induction and for NK cells we calculated an average fold
induction of 11 (Figure 2D).
Dual-Luciferase Imaging of
Antigen-Specific T Cells
In order to study dual-bioluminescent T cells with known
antigen specificity, the TbiLuc mouse was crossed to T cell
receptor-transgenic OT-I mice whose CD8T cells recognize the
SIINFEKL epitope of chicken ovalbumin (OVA) as presented in
H-2Kb MHC class I molecules. The resulting TbiLuc∗OT-I mice
showed constitutive luciferase expression in lymphoid organs,
as was the case in the parental TbiLuc mice (Figure 3A). To
study NFAT-luciferase induction in an antigen-specific manner,
we purified CD8+ T cells from the spleens of TbiLuc∗OT-I
mice by magnetic selection. This procedure yielded >90% pure
CD8T cells with a naïve phenotype (Supplementary Figure 1b).
The isolated CD8T cells were then co-incubated in vitro with
dendritic cells presenting the SIINFEKL epitope processed from
the OVA protein after uptake of immune-complexes (OVA-IC),
which we have previously reported as an efficient CD8T cell
vaccine (25). This led to a strong induction of NFAT-luciferase,
which was completely antigen-specific as control dendritic cells
did not induce any expression, identical to unstimulated naïve
T cells (Figure 3B). We calculated the fold induction of the
NFAT-luciferase after unmixing of signals. For CD8+ T cells
we found an average of 6.5 ± 1.3 -fold induction after T
cell activation using αCD3/αCD28 antibodies, an average of
81 ± 2 -fold induction when using PMA/Ionomycin and an
average of 24 ± 2 -fold induction when using OVA-IC DCs.
(Figure 3C). Western Blot analysis confirmed the presence of
PpyRE9 protein (Supplementary Figure 1c). Although the use
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FIGURE 3 | Dual-luciferase imaging of antigen-specific T cells. (A) Bioluminescence measurement of a TbiLuc*OT-I mouse, showing luciferase expression in
secondary lymphoid organs. The abdomen is shaved to reduce signal absorption. The spleen (spl) and various lymph nodes (LN) are indicated. (B) CD8T cells were
isolated from the spleen of TbiLuc*OT-I mice and stimulated overnight with agonistic CD3/CD28 antibodies, PMA + ionomycin, dendritic cells loaded with OVA protein
immune complexes (OVA-IC DCs) or with unloaded control DCs, as indicated. Subsequent bioluminescence imaging shows constitutive CBG99 expression (CD2-luc,
top), activation-induced PpyRE9 expression (NFAT-luc, middle) and an overlay of artificial green and red colors (bottom) corresponding to the spectral unmixing as
shown in the bottom-right graph. Representative data from two independent experiments. (C) Fold induction of NFAT-luciferase expression in TbiLuc*OT-I cells after
stimulation with PMA+ionomycin or αCD3+αCD28 compared to unstimulated cells, or after incubation with OVA-IC DCs compared to control DCs. Signals are
corrected for differences in constitutive hCD2-luciferase expression. Baseline expression (1-fold) is indicated by the dotted line. Representative data of two
independent experiments with n = 2 samples per group each. Mean + SD.
of a single D-luciferin substrate was sufficient for dual-color
imaging in vitro, the relatively weak NFAT-induced red luciferase
signal does not allow efficient in vivo detection of T cell
activation. Therefore, we employed the new luciferin substrate
CycLuc1, which has specifically been designed to improve light
emission from firefly luciferases such as our NFAT-induced
PpyRE9 red luciferase (18). In vivo imaging of naïve TbiLuc mice
using the CycLuc1 substrate (Supplementary Figure 2a) shows a
low constitutive CBG99 luciferase signal compared to the use of
the D-luciferin substrate as in Figure 1. Although BLI signals in
the lymphoid organs were detectable using CycLuc1, these were
10-fold lower in lymph nodes, 3-fold lower in the spleen and 5-
fold lower in the thymus when compared to BLI signals using D-
luc, while BLI signals were nearly absent in non-lymphoid organs
(Supplementary Figure 2b).
By using T cell hybridomas expressing either one of the
two luciferases also used in TbiLuc, we show that CycLuc1
is indeed an inefficient substrate for CBG99 green luciferase,
as indicated by the 30-fold lower signal at the emission peak
as compared to D-luciferin (Supplementary Figure 3a). This
allows specific detection of PpyRE9 luciferase in TbiLuc T cells
using the CycLuc1 substrate. Moreover, these data indicate that
substrates given in combination compete for the active site of
the enzymes, as shown by the 1,6 times lower average photon
flux measured for CBG99 emission with D-Luc + CycLuc1
as compared to D-Luc alone. Next, we investigated whether
dual-color imaging of TbiLuc∗OT-I T cell activation could be
performed using the two substrates, D-luciferin and CycLuc1.
Addition of a single substrate per sample allowed efficient
detection of the constitutive signal from CBG99 green luciferase
by D-luciferin, and the activation-induced signal from PpyRE9
red luciferase by CycLuc1 (Figure 4A). Unlike naïve T cells,
activated T cells expressing both luciferases produce a spectrum
with no isolated peaks of emission when the two substrates
are added simultaneously (Figure 4B). For CD8+ T cells we
found an average of 1.5 ± 0.1 -fold induction of NFAT-luciferase
expression using D-luciferin and an average of 42 ± 8 -fold
induction using CycLuc1 and an average of 7± 1 -fold induction
using combination of substrates (Figure 4C). Therefore, separate
addition of substrates is warranted for efficient separation of
light signals in activated T cells. We estimated the sensitivity of
detecting T cell activation with CycLuc1 in vitro by showing that
stimulation with agonistic anti-CD3 antibodies up to 100x below
the optimal concentration still results in NFAT-luciferase signals
detectable by CycLuc1 (Supplementary Figure 3b). In addition,
the use of the CycLuc1 substrate for visualization of activation-
induced PpyRE9 luciferase was also validated in CD4+ andCD8+
T cells from parental TbiLuc mice (Supplementary Figure 3c).
Visualization of T Cell Localization and
Activation in Vaccinated Mice
We set out to investigate whether antigen-specific target
recognition by T cells could be visualized in vivo, using
an adoptive T cell transfer system. First, we visualized the
fate of T cells after adoptive transfer. Intravenously injected
TbiLuc∗OT-I CD8+ T cells had efficiently homed to the
lymphoid organs of recipient Albino B6 mice after 1 day,
and the number of transferred T cells correlated to the signal
strength (Supplementary Figure 4). Next, mice were vaccinated
subcutaneously in the tail-base with dendritic cells (DCs) pre-
loaded with OVA protein immune complexes, containing the
specific T cell antigen recognized by OT-I T cells, while
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FIGURE 4 | Efficient visualization of NFAT-induced PpyRE9 luciferase using the CycLuc1 substrate. (A) CD8T cells from TbiLuc*OT-I mice left untreated (“Naive T
cells”) or stimulated overnight with OVA immune complex-loaded dendritic cells (“Activated T cells”) were imaged using the substrate D-luciferin (D-luc), CycLuc1, or
both, as indicated. Total signal (top), the constitutive green CD2-luciferase (middle) and the activation-induced red NFAT-luciferase (bottom) are shown separately, all
on the same scale. (B) Emission spectra of naive T cells and of activated T cells (from Figure A) using different substrates, showing strong constitutive CBG99 signals
using the D-luciferin substrate, and specific activation-induced PpyRE9 signals using CycLuc1. (C) Fold induction of NFAT-luciferase expression in TbiLuc*OT-I cells
after incubation with OVA-IC DCs compared to unstimulated cells and BLI measurement using D-luc, CycLuc1 or both. Signals are corrected for differences in
constitutive CD2-luciferase expression. Mean + SD. Representative data from two independent experiments.
control mice received unloaded DCs. Based on previous in vitro
results, we adopted an in vivo imaging protocol with separate
administration of the two substrates with a 3 h time interval to
allow clearance of the first substrate D-luciferin (as assured by
imaging the mouse prior to injection of the second substrate)
measuring CBG99 luciferase activity, followed by measurement
of PpyRE9 luciferase activity using the CycLuc1 substrate. This
order was chosen based on the longer half-life of the second
substrate CycLuc1 compared to the first substrate D-luciferin
(18). Periodical bioluminescence imaging was then performed,
focusing on the vaccine-draining inguinal lymph nodes, and the
green and red light signals were quantified. In the first week
after vaccination, OVA-vaccinated mice showed a sharp increase
in both the constitutive green light signal and the activation-
induced red light signal in the lymph nodes, peaking at day 8 after
injection (Figure 5A). In contrast, control mice had a comparable
constitutive green light signal on day 2 as OVA-vaccinated mice,
but did not show a strong T cell expansion and no red light
signal above background, suggesting that the DC-OVA vaccine
specifically induced activation and expansion of TbiLuc∗OT-I
T cells. Two days after vaccination, T cell activation could be
detected by means of PpyRE9 luciferase activity, while T cell
expansion as measured by CBG99 luciferase activity started later
in time. The dramatic increase in luciferase activity in OVA-
vaccinated mice, and the lack of NFAT-dependent red luciferase
activity in control mice, can be seen in representative images
from day 8 (Figure 5B). To estimate the sensitivity of the TbiLuc
mouse model for detecting T cell activation in vivo, we repeated
the DC-OVA vaccination experiment using lower numbers of
DC-OVA cells used as a vaccine, ranging from 10- to 1000-fold
lower than the optimal condition of 1 million cells as used in
Figure 5, while the number of TbiLuc∗OT-I T cells remained
the same. Imaging of vaccine-draining lymph nodes of mice
vaccinated with 10-fold fewer DC-OVA cells showed robust and
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FIGURE 5 | Visualization of T cell localization and activation in vaccinated mice. (A) Constitutive CD2-luciferase (left) and NFAT-luciferase (right) signals from
vaccine-draining inguinal lymph nodes of vaccinated mice. On day 0, mice received adoptive transfer of TbiLuc*OT-I CD8+ T cells and were vaccinated with OVA
immune complex-preloaded dendritic cells or with unloaded control dendritic cells. Two representative mice are shown per group from a total of 4 mice per group.
CD2-CBG99 and NFAT-PpyRE9 luciferases were visualized using the D-luciferin and CycLuc1 substrates, respectively. Mice receiving the control vaccine showed no
detectable NFAT-luc signal after subtraction of background. Statistical significance of differences in signal compared to day 2 is indicated by asterisks, *p < 0.05. (B)
Representative pictures of OVA-vaccinated and control-vaccinated mice on day 8, showing dramatic T cell proliferation (left) and activation (right) in OVA-vaccinated
mice.
quantifiable T cell activation, while also a vaccine dose of 100-
fold below optimal still produced detectable T cell activation,
indicating that the TbiLuc mouse model can detect T cell
responses in suboptimal conditions (Supplementary Figure 5).
Taken together, these results proof-of-concept for the use of the
TbiLuc model to longitudinally visualize T cell responses in vivo.
DISCUSSION
In this study, we report on the design and development of a dual-
luciferase T cell transgenic mouse, called TbiLuc, as a novel tool
for non-invasive imaging of T cells. The dual-luciferase construct
allows live visualization of both the location and the activation
status of T cells, which we established in antigen-specific T cell
activation studies both in vitro and in vivo. The TbiLuc mouse
model has numerous applications both in fundamental T cell
biology and in preclinical translational studies on the many
diseases in which T cells play a role. For instance, since it has
been established that T cells are crucial in the spontaneous or
therapeutically-induced clearance of malignant cells, the TbiLuc
mouse can be used to test the efficacy of cancer vaccines,
immunomodulatory antibodies and other treatment modalities
that depend on T cells. Disease models of viral infection and
autoimmunity involving T cell effector cells are other possible
applications of the TbiLuc mouse (26, 27).
To introduce luciferase-encoding genes into cells, researchers
commonly use retroviral transduction. However, naïve T cells
cannot be efficiently transduced unless they are pre-treated by
either TCR stimulation with cognate antigen or with cytokines
such as IL-7, both of which trigger downstream signaling
pathways in the T cells (6–9, 28, 29). This makes studies on truly
naïve T cells impossible, although T cell “rested” after activation
and transduction are sometimes considered to represent naïve
T cells; a perhaps more pragmatic rather than immunological
interpretation. Instead, integration of a luciferase-encoding
gene into murine oocytes, resulting in a luciferase-transgenic
mouse strain, is a time-consuming but scientifically much more
attractive alternative that allows the isolation of luciferase-
expressing naïve T cells from the lymphoid organs of the
mouse. Indeed, several groups have created luciferase reporter
mice for T cell imaging and showed the potential of BLI
for T cell tracking (10–12). However, these single-luciferase
reporter mice only provide information on the location of
T cells, without additional information on their activation
state. The feasibility of creating dual-luciferase transgenic
mice has been shown before, but never using cell type-specific
expression (30, 31). We describe the first dual-luciferase T cell
transgenic mouse employing D-luciferin analogs, which offers
an important advantage in allowing simultaneous visualization
of T cell location and activation. For transgenesis, we chose to
randomly integrate our construct and select founders for high
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constitutive green luciferase expression. As the length of the
genetic construct (more than 10 kb) influences the efficiency of
transgenic production, the inclusion of fluorescent markers in
the construct was avoided.We did not use the CRISPR-Cas9 gene
knock-in system for transgenesis as it suffers from suboptimal
efficiency (1–10%), especially for constructs longer than
2 kb (32).
Luciferase T cell imaging, and optical imaging in general, is
especially well-suited for visualization of superficial light signals,
as the signal from deeper locations in the body will be influenced
by absorption and scattering of photons in the tissues. In this
view, radio-imaging provides more accurate information on the
location of T cells (33, 34). However, optical imaging strategies
avoid the undesired use of radioactive material, and BLI in
particular allows the creation of reporter mice where luciferase
expression can be restricted to the cell type of choice by choosing
a cell-specific promoter. Our choice of the human CD2 minigene
as the promoter driving the constitutively expressed CBG99
luciferase is based on earlier studies showing T cell-specific
transgene expression (20, 21). The transgenic mouse described
by Szyska et al. instead expresses Renilla luciferase under the
control of a ubiquitous constitutive promoter, which means that
specific T cell tracking is only possible using an experimental
setup of T cell isolation and adoptive transfer (13). In the TbiLuc
model, the NFAT response element driving PpyRE9 luciferase
expression allows a straightforward readout of T cell function,
which is valuable extra information besides the location of the
T cell. We demonstrated that T cell isolated from TbiLuc and
TbiLuc∗OT-I mice can be used for cell-based assays using a
single substrate D-luciferin. On the other hand, an optimized
protocol had to be developed for in vivo imaging. A limitation
of the dual-color system using a single D-luciferin substrate
in vivo is the fact that red photons detected in vivo could be
derived from the green luciferase located in deep tissues, based on
the superior tissue penetration of high-wavelength (red shifted)
photons, as we have described before (17). In addition, NFAT-
driven luciferase activity may be observed in non-T cells, as
we have shown for NK cells after PMA+ionomycin treatment,
however, these cells can be distinguished from T cells because of
the absence of green CD2-driven luciferase emission. Moreover,
in models using adoptive T cell transfer, NK cells are efficiently
excluded during the T cell isolation process. Besides activated
T cells, dual-luciferase signals could possibly also be observed
during T cell exhaustion, which has been described to be induced
by NFAT (35).
Our optimized in vivo imaging protocol involves separate
injection of the two substrates such that the first substrate is
cleared before the second substrate is administered, measuring
CBG99 activity using D-luciferin and measuring PpyRE9 activity
using CycLuc1. This setup provides the maximal light emission
for each luciferase and avoids both biochemical interference
from the other substrate and spectral interference from the
other luciferase. An in vivo vaccination study visualized the
expansion and activation of adoptively transferred T cells in
vaccine-draining lymph nodes following typical kinetics of T cell
responses upon vaccination (36–38). The sensitivity of TbiLuc
in vivo imaging matched that of a recently reported T cell
reporter mouse model, reaching comparable photon fluxes even
as we use much a shorter signal acquisition time of 30 s (13).
The use of longer acquisition times would likely allow the
detection of signals using lower numbers of transferred T cells.
A direct quantitative comparison of TbiLuc sensitivity with other
bioluminescence reporter systems is complicated by the fact that
the sensitivity of a bioluminescence system in vivo depends not
only on the imaging settings but also on the luciferase-luciferin
couple.
Our data have shown that dual-luciferase reporter mice can
be easily crossed to other (T cell-) transgenic mouse strains,
which brings many possibilities to further fine-tune the reporter
system for the biomedical experimental model of interest.
Future studies using TbiLuc mice to study T cell dynamics
and functionality in diverse experimental (disease) models will
help determine the breadth of its applicability. Taken together,
this proof-of-concept manuscript introduces the TbiLuc dual-
luciferase T cell transgenic mouse that allows to track activation
and expansion of T cell populations in naturally organized
lymphoid tissue, with full retention of T cell naivety and
antigen-specific functionality. Many biomedical research fields
can potentially benefit from this advanced live T cell imaging
model.
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